Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 11/20 | 0.75 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.49 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | P2RX6 | O15547 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
| ▸ | P2RX5 | Q93086 | 1/20 | 0.46 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799127 | 1.00 | TYMP (0.75) | TYMPENPP1ADORA1P2RX3P2RX4 | |
| SCHEMBL17889851 | 1.00 | TYMP (0.75) | TYMPENPP1ADORA1P2RX3P2RX4 | |
| SCHEMBL1799132 | 1.00 | TYMP (0.75) | TYMPENPP1ADORA1P2RX3P2RX4 | |
| SCHEMBL1795887 | 0.91 | TYMP (0.66) | TYMPENPP1ADORA1P2RX3P2RX4 | |
| SCHEMBL17889864 | 0.91 | TYMP (0.66) | TYMPENPP1ADORA1P2RX3P2RX4 | |
| SCHEMBL1795889 | 0.91 | TYMP (0.66) | TYMPENPP1ADORA1P2RX3P2RX4 | |
| SCHEMBL6269464 | 0.91 | TYMP (0.66) | TYMPENPP1ADORA1P2RX3P2RX4 | |
| SCHEMBL1795885 | 0.91 | TYMP (0.66) | TYMPENPP1ADORA1P2RX3P2RX4 | |
| SCHEMBL8610982 | 0.88 | TYMP (0.83) | TYMPADORA1 | |
| SCHEMBL6268270 | 0.87 | TYMP (0.57) | TYMPENPP1ADORA1P2RX3P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-1848718-B1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARM INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1848718-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| WO-2006084281-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | TYMP 1/4885ENPP1 9/4885ADORA1 857/4885 |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | TYMP 270/4885ENPP1 18/4885ADORA1 2055/4885 |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | TYMP 4/4885ENPP1 2102/4885ADORA1 232/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | TYMP 270/4885ENPP1 18/4885ADORA1 2055/4885 |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | TYMP 4/4885ENPP1 2102/4885ADORA1 232/4885 |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | TYMP 270/4885ENPP1 18/4885ADORA1 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.